0.5 billion Anti-allergy Drugs Meet Reviewers Again Only 3 Varieties in 4.9 billion Market


Release time:

2019-04-13

On November 24, AstraZeneca's PD-L1 Durvalumab injection (Imfinzi) application for listing in China was in the "under approval" state, and it is expected that it will soon be approved as the first PD-L1 monoclonal antibody drug listed in China for the treatment of inoperable stage III non-small cell lung cancer.

The first PD-L1 monoclonal antibody in China will be approved soon.

On November 24, AstraZeneca's PD-L1 Durvalumab injection (Imfinzi) application for listing in China was in the "under approval" state. It is expected that it will soon be approved as the first PD-L1 monoclonal antibody drug listed in China for the treatment of inoperable stage III non-small cell lung cancer.

0.5 billion Anti-allergy Drugs Meet Reviewers Again Only 3 Varieties in 4.9 billion Market

On the evening of November 24, Hainan Puli Pharmaceutical issued an announcement stating that the company recently received the "Drug Supplement Application Approval" for desloratadine tablets (5mg) issued by the State Food and Drug Administration, and the product passed the consistency evaluation. According to the data of the intranet, the market for terminal systemic antihistamines in public medical institutions in China was 4.906 billion yuan in 2018, and only three varieties have been evaluated by enterprises.

Roche "pertuzumab" third indications approved soon

On November 22, Roche's innovative targeted breast cancer drug Pasett®(English trade name: Perjeta®, generic name: pertuzumab) new indication listing application (acceptance number JXSS1800042) processing status changed to under examination and approval, which will be the third indication approved by Patete in the Chinese market after being approved for listing for the first time last year.